After a PhII catastrophe wiped out a billion dollars in market cap, Seres is looking for a do-over
Last summer, shares of Seres Therapeutics $MCRB were shredded by a failed Phase II study for their lead microbiome drug program, wiping out a billion dollars of market cap.
The setback not only raised serious questions about Seres and its expertise in the field, as the most advanced microbiome study in the industry it also cast a pall over the whole field of microbiome R&D, the use of teeming multitudes of bacteria in the gut to fix what ails you.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
